每經AI快訊，截至(zhi)8月29日晚間，據(ju)同(tong)花(hua)順iFind數據(ju)顯示，已有64家中(zhong)(zhong)(zhong)藥(yao)上市(shi)公司公布2023年上半(ban)年成(cheng)(cheng)績(ji)單。近八成(cheng)(cheng)實(shi)現營(ying)(ying)收(shou)、凈利潤雙升，其(qi)中(zhong)(zhong)(zhong)營(ying)(ying)收(shou)增幅最大的為隴神戎(rong)發，同(tong)比(bi)增長(chang)113.94%；歸母凈利潤增幅最大的則是(shi)太極集(ji)團，同(tong)比(bi)增長(chang)342.26%。 不過，值得一提的是(shi)，在中(zhong)(zhong)(zhong)藥(yao)上市(shi)公司業(ye)績(ji)普遍增長(chang)的態勢下，其(qi)營(ying)(ying)業(ye)成(cheng)(cheng)本也隨之“水漲(zhang)船高”，上述64家中(zhong)(zhong)(zhong)藥(yao)上市(shi)公司中(zhong)(zhong)(zhong)，逾八成(cheng)(cheng)營(ying)(ying)業(ye)總成(cheng)(cheng)本同(tong)比(bi)增長(chang)。（證(zheng)券日報）